| Basics |
BioCryst Pharmaceuticals, Inc.
Biocryst Pharmaceuticals Inc is a pharmaceutical company that designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in the infectious and inflammatory diseases. It has its focus on oral treatments for rare diseases.
|
| IPO Date: |
March 4, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.83B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.21 | 3.06%
|
| Avg Daily Range (30 D): |
$0.17 | 1.68%
|
| Avg Daily Range (90 D): |
$0.20 | 2.27%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.52M |
| Avg Daily Volume (30 D): |
2.89M |
| Avg Daily Volume (90 D): |
3.67M |
| Trade Size |
| Avg Trade Size (Sh.): |
179 |
| Avg Trade Size (Sh.) (30 D): |
115 |
| Avg Trade Size (Sh.) (90 D): |
133 |
| Institutional Trades |
| Total Inst.Trades: |
3,672 |
| Avg Inst. Trade: |
$2.25M |
| Avg Inst. Trade (30 D): |
$3.36M |
| Avg Inst. Trade (90 D): |
$3.3M |
| Avg Inst. Trade Volume: |
.27M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.12M |
| Avg Closing Trade (30 D): |
$4.8M |
| Avg Closing Trade (90 D): |
$4.03M |
| Avg Closing Volume: |
378.17K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.26
|
$
|
$-.13
|
|
Diluted EPS
|
$-.26
|
$
|
$-.13
|
|
Revenue
|
$ 503.49M
|
$ 145.53M
|
$ 131.53M
|
|
Gross Profit
|
$ 487.91M
|
$ 140.97M
|
$ 125.44M
|
|
Net Income / Loss
|
$ -53.47M
|
$ .03M
|
$ -26.8M
|
|
Operating Income / Loss
|
$ 33.17M
|
$ 21.23M
|
$ -4.51M
|
|
Cost of Revenue
|
$ 15.57M
|
$ 4.57M
|
$ 6.09M
|
|
Net Cash Flow
|
$ 20.75M
|
$ .56M
|
$ 7.26M
|
|
PE Ratio
|
|
|
|
|
|
|
